Organogenesis Holdings Inc. (ORGO)
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Organogenesis Holdings Inc.
No splits on record
Nothing in ORGO's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Revenue | $563.03M | $482.04M | $433.14M | $450.89M | $467.36M | $338.3M | $260.98M | $193.45M | $0 | $0 |
| YoY Growth | 16.8% | 11.3% | -3.9% | -3.5% | 38.2% | 29.6% | 34.9% | - | - | - |
| Cost of Revenue | $137.52M | $115.74M | $106.48M | $105.02M | $114.2M | $87.32M | $75.95M | $68.81M | $4.59M | $209K |
| Gross Profit | $425.51M | $366.3M | $326.66M | $345.87M | $353.16M | $250.98M | $185.03M | $124.64M | -$4.59M | -$209K |
| Gross Margin | 75.6% | 76.0% | 75.4% | 76.7% | 75.6% | 74.2% | 70.9% | 64.4% | - | - |
| Research and Development | $44.54M | $50.27M | $44.38M | $39.76M | $30.74M | $20.09M | $14.8M | $10.74M | $0 | $0 |
| Selling, General, and Administrative | $326.24M | $294.51M | $269.75M | $283.81M | $250.2M | $204.19M | $200.09M | $161.96M | $4.59M | $209K |
| Other | -$1.14M | $22.8M | $0 | $0 | $0 | $0 | $0 | $162K | $0 | $209K |
| Total Operating Expenses | $369.64M | $367.58M | $314.13M | $323.57M | $280.94M | $224.28M | $214.89M | $172.7M | $4.59M | $209K |
| Operating Income (EBIT) | $55.87M | -$1.28M | $12.53M | $22.3M | $72.22M | $26.7M | -$29.85M | -$51.56M | -$4.59M | $209K |
| Operating Margin | 9.9% | -0.3% | 2.9% | 4.9% | 15.5% | 7.9% | -11.4% | -26.7% | - | - |
| Interest Expense | $0 | $1.54M | $2.19M | $2.01M | $7.24M | $11.28M | $9M | $10.85M | $8.01M | $5.63M |
| Interest Income | $2.28M | $0 | $0 | $0 | $0 | $0 | $0 | $64K | $0 | $153K |
| Other Income (Expense) | -$8.9M | -$1.52M | -$2.13M | -$2.02M | -$9.13M | -$8.94M | -$8.71M | -$13.19M | $3.4M | $8.57M |
| Income Before Tax (EBT) | $46.97M | -$2.81M | $10.39M | $20.28M | $63.09M | $17.76M | -$38.56M | -$64.75M | -$2.09M | -$209K |
| Income Tax Expense | $9.94M | -$3.67M | $5.45M | $4.75M | -$31.12M | $530K | $150K | $84K | -$53K | -$440K |
| Net Income | $37.03M | $861K | $4.95M | $15.53M | $94.2M | $17.23M | -$38.71M | -$64.83M | -$2.09M | -$209K |
| Net Income Margin | 6.6% | 0.2% | 1.1% | 3.4% | 20.2% | 5.1% | -14.8% | -33.5% | - | - |
| Supplementary Data | ||||||||||
| EPS | 0.16 | -0.01 | 0.04 | 0.12 | 0.73 | 0.16 | -0.44 | -0.94 | -0.03 | -0.02 |
| Diluted EPS | 0.15 | -0.01 | 0.04 | 0.12 | 0.70 | 0.15 | -0.44 | -0.94 | -0.03 | -0.02 |
| Weighted Average OS | 126.74M | 131.67M | 131.23M | 130.07M | 128.33M | 107.74M | 92.84M | 68.97M | 63.88M | 8.58M |
| EBITDA | $73.91M | $15.76M | $36.03M | $40.32M | $87M | $37.23M | -$19.74M | -$46.92M | -$2.09M | $7.11M |
| EBITDA Margin | 13.1% | 3.3% | 8.3% | 8.9% | 18.6% | 11.0% | -7.6% | -24.3% | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
| Assets | |||||||||||
| Current Assets | |||||||||||
| Cash and Cash Equivalents | $93.68M | $135.57M | $104.34M | $102.48M | $113.93M | $84.39M | $60.17M | $21.29M | $126K | $1.04M | $126K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $93.68M | $135.57M | $104.34M | $102.48M | $113.93M | $84.39M | $60.17M | $21.29M | $126K | $1.04M | $126K |
| Accounts Receivable | $217.45M | $109.86M | $82M | $89.45M | $82.46M | $56.8M | $39.36M | $34.08M | $0 | $0 | $0 |
| Inventory | $29.63M | $26.22M | $28.25M | $24.78M | $25.02M | $27.8M | $22.92M | $13.32M | $0 | $0 | $0 |
| Other Current Assets | $21.43M | $5.67M | $1.19M | $5.1M | $711K | $584K | $1.1M | $353K | $0 | $0 | $0 |
| Total Current Assets | $362.19M | $285.94M | $225.04M | $222.61M | $226.98M | $174.34M | $125.6M | $71.13M | $294K | $1.44M | $126K |
| Long-Term Assets | |||||||||||
| Property, Plant & Equipment Net | $159.46M | $126.24M | $156.35M | $145.66M | $128.3M | $55.79M | $47.18M | $39.62M | $0 | $0 | $0 |
| Goodwill | $28.77M | $28.77M | $28.77M | $28.77M | $28.77M | $28.77M | $25.54M | $25.54M | $0 | $0 | $0 |
| Intangible Assets | $9.14M | $12.47M | $15.87M | $20.79M | $25.67M | $30.62M | $20.8M | $26.09M | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $15.87M | $0 | $0 | $0 | $0 | $477K | $312.5M | $310M | $0 |
| Deferred Tax Assets | $29.96M | $39.46M | $28M | $30.01M | $31.99M | $18K | $127K | $238K | $0 | $0 | $0 |
| Other Long-Term Assets | $9.2M | $5M | -$9.88M | $1.52M | $1.54M | $670K | $1.44M | $579K | $0 | $0 | $290K |
| Total Long-Term Assets | $236.54M | $211.94M | $234.98M | $226.75M | $216.28M | $115.87M | $95.09M | $92.55M | $312.5M | $310M | $290K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $598.73M | $497.89M | $460.02M | $449.36M | $443.26M | $290.22M | $220.69M | $163.68M | $312.79M | $311.44M | $416K |
| Liabilities | |||||||||||
| Current Liabilities | |||||||||||
| Accounts Payable | $31.95M | $28.91M | $30.72M | $32.33M | $29.34M | $23.38M | $28.39M | $19.16M | $19.05M | $0 | $0 |
| Short-Term Debt | $18.64M | $0 | $5.49M | $4.54M | $2.66M | $16.67M | $0 | $2.54M | $100K | $0 | $175K |
| Current Income Tax Payable | $0 | $4.29M | $2.8M | $2.63M | $1.16M | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $30.41M | $0 | $0 | $0 |
| Other Current Liabilities | $49.53M | $25.29M | $22.17M | $9.33M | $29.44M | $21.58M | $25.58M | $22.22M | -$30.01M | $0 | $0 |
| Total Current Liabilities | $100.12M | $77.48M | $80.51M | $75.02M | $82.7M | $68.22M | $59.89M | $66.39M | $3.93M | $478K | $416K |
| Long-Term Liabilities | |||||||||||
| Long-Term Debt | $50.71M | $0 | $60.74M | $66.23M | $70.77M | $53.04M | $83.12M | $39.06M | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $130K | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | -$49.51M | $894K | $1.21M | $1.12M | $1.56M | $15.71M | $7.66M | $903K | -$1.54M | $10.85M | $0 |
| Total Long-Term Liabilities | $64.69M | $35.09M | $100.85M | $108.67M | $119.22M | $80.19M | $105.21M | $50.25M | $10.85M | $10.85M | $175K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$175K |
| Total Liabilities | $164.81M | $112.57M | $181.36M | $183.69M | $201.92M | $148.41M | $165.1M | $116.64M | $14.78M | $11.33M | $416K |
| Stockholders' Equity | |||||||||||
| Preferred Stock | $133.79M | $122.42M | $0 | $0 | $0 | $0 | $0 | $0 | $293.01M | $295.11M | $0 |
| Common Stock | $13K | $13K | $13K | $13K | $13K | $13K | $10K | $9K | $293.01M | $295.11M | $863 |
| Retained Earnings | -$3.08M | -$40.11M | -$40.97M | -$45.3M | -$60.83M | -$155.03M | -$171.01M | -$130.24M | -$2.33M | -$234K | -$25K |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$293.01M | -$295.11M | $0 |
| Other Stockholders' Equity | $436.98M | $425.41M | $319.62M | $310.96M | $302.15M | $296.83M | $226.58M | $177.27M | $7.33M | $5.23M | $24K |
| Total Equity | $433.92M | $385.32M | $278.66M | $265.67M | $241.34M | $141.81M | $55.58M | $47.04M | $298.01M | $300.11M | -$162 |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $598.73M | $497.89M | $460.02M | $449.36M | $443.26M | $290.22M | $220.69M | $163.68M | $312.79M | $311.44M | $416K |
| Supplementary Data | |||||||||||
| Total Debt | $132.84M | $43.31M | $119.35M | $123.79M | $132.3M | $84.77M | $100.61M | $59.26M | $17.86M | $0 | $175K |
| Net Debt | $39.16M | -$92.26M | $15.01M | $21.31M | $18.37M | $377K | $40.43M | $37.97M | $17.73M | -$1.04M | $49K |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
| Operating Activities | |||||||||||
| Net Income | $37.03M | $861K | $4.95M | $15.53M | $94.9M | $17.23M | -$40.45M | -$64.83M | -$2.09M | -$209K | -$24.26M |
| Depreciation & Amortization | $26.94M | $17.03M | $23.45M | $18.03M | $16.68M | $8.18M | $9.83M | $6.98M | $5.63M | $7.32M | $7.68M |
| Deferred Income Tax | $9.5M | -$10.72M | $2.01M | $1.98M | -$31.98M | $112K | $111K | $186K | $0 | $0 | $0 |
| Stock-Based Compensation | $13.3M | $10.58M | $9M | $6.55M | $3.86M | $1.66M | $936K | $1.07M | $919K | $473K | $459K |
| Changes in Working Capital: | |||||||||||
| Accounts Receivable | -$115.8M | -$31.8M | $5.54M | -$8.77M | -$30.23M | -$17.57M | -$4.69M | -$7.11M | -$7.01M | -$6.56M | $1.41M |
| Inventory | -$17.91M | -$6.2M | $6.58M | -$9.41M | -$9.3M | -$6.7M | -$11.06M | -$5M | -$1.49M | -$5.37M | -$8.2M |
| Accounts Payable | -$528K | -$2.37M | -$108K | $3.26M | $3.85M | -$4.1M | $4.7M | -$60K | $0 | $0 | $0 |
| Other Working Capital | $1.86M | -$8.51M | -$30.08M | -$19.16M | -$3.6M | $612K | $1.39M | -$10.23M | $1.51M | $8K | $3.9M |
| Total Working Capital Change | -$132.38M | -$48.89M | -$18.07M | -$34.08M | -$39.29M | -$27.76M | -$9.67M | -$22.4M | $1.51M | -$354K | -$2.89M |
| Other Non-Cash Items | $35.3M | $45.35M | $9.59M | $16.85M | $17.8M | $6.03M | $5.72M | $18.25M | -$156K | -$303.8M | $8.81M |
| Net Cash from Operating | -$10.31M | $14.21M | $30.92M | $24.86M | $61.98M | $5.47M | -$33.53M | -$60.74M | -$587K | -$562K | -$10.19M |
| Investing Activities | |||||||||||
| Capital Expenditures | -$14.15M | -$10.03M | -$24.36M | -$33.9M | -$31.22M | -$17.68M | -$6.23M | -$1.86M | -$2.43M | -$1.36M | -$510K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | -$5.82M | $0 | $1K | -$11.79M | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1K | -$658K | -$310M | $121K |
| Net Cash from Investing | -$14.15M | -$10.03M | -$24.36M | -$33.9M | -$31.22M | -$23.5M | -$6.23M | -$1.86M | -$14.87M | -$310M | -$389K |
| Financing Activities | |||||||||||
| Debt Repaid | $1.17M | $67.64M | $5.17M | $3.01M | $2.01M | $15.91M | -$30.23M | -$1.07M | -$21.01M | -$11.98M | - |
| Common Stock Issuance | $157K | $0 | $0 | $0 | $2.2M | $64.73M | $50.34M | $92M | -$428K | $303.8M | $0 |
| Common Stock Repurchases | $0 | -$25.48M | $0 | $0 | $0 | $0 | -$6.76M | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | -$1.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$16.35M | $1.87M | -$332K | $814K | -$1.22M | -$6.35M | $50.34M | $80.72M | $19.19M | -$5.2M | $10.79M |
| Net Cash from Financing | -$17.36M | $27.64M | -$5.5M | -$2.2M | -$1.04M | $42.47M | $78.73M | $81.64M | -$328K | $311.48M | $10.79M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$41.82M | $31.81M | $1.05M | -$11.24M | $29.72M | $24.44M | $38.97M | $19.05M | -$914K | $914K | $204K |
| Supplementary Data | |||||||||||
| Operating Cash Flow | -$10.31M | $14.21M | $30.92M | $24.86M | $61.98M | $5.47M | -$33.53M | -$60.74M | -$587K | -$562K | -$10.19M |
| Capital Expenditure | -$14.15M | -$10.03M | -$24.36M | -$33.9M | -$31.22M | -$17.68M | -$6.23M | -$1.86M | -$2.43M | -$1.36M | -$510K |
| Free Cash Flow | -$24.46M | $4.18M | $6.55M | -$9.04M | $30.76M | -$12.21M | -$39.76M | -$62.6M | -$3.01M | -$1.92M | -$10.7M |
| Cash at Beginning | $136.15M | $104.34M | $103.29M | $114.53M | $84.81M | $60.37M | $21.41M | $2.36M | $1.04M | $126K | $995K |
| Cash at End | $94.33M | $136.15M | $104.34M | $103.29M | $114.53M | $84.81M | $60.37M | $21.41M | $126K | $1.04M | $1.2M |